On Jan. 27, 2020, the Centers for Medicare & Medicaid Services (CMS) expanded coverage of FDA-approved laboratory diagnostic tests that use next generation sequencing (NGS) for patients with germline, or inherited, ovarian or breast cancer. CMS also gave the Medicare Administrative Contractors (MACs) the ability to determine coverage of NGS laboratory tests for other inherited cancers.
Read CMS Decision Memo for NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450R).
Read CMS announcement.
Posted 1/28/2020
